Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 2/20 | 0.42 |
| ▸ | LITAF | Q99732 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | ABL2 | P42684 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16767775 | 1.00 | HSD11B1 (0.46) | HSD11B1BTKTNFLITAFOPRM1 | |
| SCHEMBL29531255 | 1.00 | HSD11B1 (0.46) | HSD11B1BTKTNFLITAFOPRM1 | |
| SCHEMBL16896153 | 0.90 | EGFR (0.45) | BTKTNFLITAFOPRM1OGFRL1 | |
| SCHEMBL16896151 | 0.90 | EGFR (0.45) | BTKTNFLITAFOPRM1OGFRL1 | |
| SCHEMBL29531461 | 0.90 | EGFR (0.45) | BTKTNFLITAFOPRM1OGFRL1 | |
| SCHEMBL16901721 | 0.86 | BTK (0.43) | BTKTNFLITAFOPRM1OGFRL1 | |
| SCHEMBL16901720 | 0.86 | BTK (0.43) | BTKTNFLITAFOPRM1OGFRL1 | |
| SCHEMBL19037547 | 0.86 | BTK (0.42) | BTKTNFLITAFOPRM1OGFRL1 | |
| SCHEMBL26132563 | 0.85 | EGFR (0.43) | HSD11B1OGFRL1EGFRCYP2D6PRMT5 | |
| SCHEMBL26606547 | 0.85 | EGFR (0.43) | HSD11B1OGFRL1EGFRCYP2D6PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180153899-A1 | PHARMACEUTICAL COMPOSITIONS | NOVARTIS PHARMA AG (CH) | 2018-06-07 | — | — | US | disclosed |
| EP-3257848-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY | Novartis AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| EP-2773635-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-9440957-B2 | Compounds and compositions for modulating EGFR Activity | NOVARTIS AG (CH) | 2016-09-13 | — | — | US | disclosed |
| US-9440957-B2 | Compounds and compositions for modulating EGFR Activity | NOVARTIS AG (CH) | 2016-09-13 | — | — | US | disclosed |
| US-20150197505-A1 | Compounds and Compositions for Modulating EGFR Activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-07-16 | — | — | US | disclosed |
| US-20150197505-A1 | Compounds and Compositions for Modulating EGFR Activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-07-16 | — | — | US | disclosed |
| WO-2015081463-A1 | EGFR INHIBITOR FORMS | NOVARTIS AG (CH) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197505-A1 | Compounds and Compositions for Modulating EGFR Activity | EGFR, ERBB2, ERBB3 | HSD11B1 3822/4885BTK 77/4885TNF 2084/4885 |
| US-20180153899-A1 | PHARMACEUTICAL COMPOSITIONS | NR3C2, PTMS, CYP2C19 | HSD11B1 161/4885BTK 2280/4885TNF 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.